Impact of TheraWorx Foam on Symptom Relief in Thumb Arthritis
Status:
Completed
Trial end date:
2020-08-01
Target enrollment:
Participant gender:
Summary
Thumb carpometacarpal osteoarthritis (CMC OA) affects up to 33% of people over the age of 40,
which leads to inflammation, pain, and weakness of the CMC joint. Treatment modalities are
both conservative and surgical with surgical options including osteotomy, bone excision,
ligament reconstruction, and various prosthetic implants. The conservative treatment options,
however, are limited to NSAIDs and bracing or steroid injections.
Advances in topical therapies have the potential to deliver focused treatment to the CMC
joint. Novel treatment of inflammation can potentially reduce inflammation and pain
associated with progressing osteoarthritis. Theraworx Relief is an FDA registered foam that
has theoretical impact on inflammation reduction in human subjects treated with the topical
foam.